logo

English
  • Svenska
  • About Us
    About Us
      • This is Calliditas
      • Vision and Strategy
      • Board of Directors
      • Management Team
      • Our History
      • Corporate Responsibility
        • Expanded Access Policy
      • Careers
  • Science
    Science
      • Our Pipeline
      • Nefecon (ex-US Markets)
      • Setanaxib – NOX Platform
      • Orphan drugs
  • Our Product
  • Governance
    Governance
      • Corporate Governance
      • Corporate Governance Reports
      • Corporate Structure
      • General Meeting
        • Annual general meeting 2022
        • General meetings
      • Nomination Committee
        • Nomination committees
      • Board and Committees
        • Board of Directors
        • Board fees
        • Work of the Board of Directors
        • Committees
      • Management
        • Management team
      • Remuneration
      • Internal Control and Risk Management
      • Auditor
      • Articles of Association
  • Investors
    Investors
      • The Share
        • Trading information
        • Ownership structure
        • Share capital development
        • Dividend policy
        • Analyst coverage
      • Financial Reports and Presentations
      • SEC Filings
      • Press Releases
      • Financial Calendar
      • IR Calendar
      • Subscribe
      • Contacts
      • Investor FAQs
  • Media
    Media
      • Press releases
      • Calliditas in Media
      • Calliditas Media Kit
      • TARPEYO Media Kit (US audience only)
      • Subscribe
      • Contacts
  • Contact Us
    Contact Us
      • Offices
      • Partnerships and Inquires
      • Investor Relations
      • Media
      • Medical Inquiries
  • Svenska

Press Releases

Read the latest press releases from Calliditas Therapeutics by clicking on a title below.

For press enquiries please contact us.

Non-regulatory press releases
  • Regulatory press releases
  • All press releases
2019
  • 2022
  • 2021
  • 2020
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2012
  • 2010
  • 2009
  • 2008
  • All years
Dec 23, 2019

The pivotal Phase 3 clinical trial NefIgArd Part A fully recruited

Nov 4, 2019

Calliditas Therapeutics Capital Markets Day today November 4

Oct 1, 2019

Save the date: Calliditas to host Capital Markets Day in Stockholm on November 4, 2019

Aug 12, 2019

Calliditas Therapeutics to host conference call to provide Business Update and 2019 Q2 report

Jun 4, 2019

Calliditas Therapeutics to Present at Redeye Growth Day

May 6, 2019

Calliditas Therapeutics to host conference call to provide Business Update and 2019 Q1 report

Apr 5, 2019

Elmar Schnee and Diane Parks proposed as new board members of Calliditas Therapeutics

Apr 3, 2019

Calliditas Therapeutics to Present at the Needham Healthcare Conference

Mar 4, 2019

Calliditas Therapeutics to Present at March Investor Conferences

Feb 1, 2019

Calliditas Therapeutics to host conference call to provide Business Update and 2018 full-year report

Jan 14, 2019

Calliditas Therapeutics appoints Frank Bringstrup as VP Regulatory Affairs

Jan 8, 2019

Calliditas Therapeutics appoints Andrew Udell to VP Commercial, North America

  • Media
    • Press Releases
    • Calliditas in Media
    • Subscribe
    • Contacts

Calliditas Therapeutics AB
D5, Kungsbron 1
SE-111 22 Stockholm
Sweden

Company number: 556659-9766

  • Privacy policy
  • About cookies

© Calliditas Therapeutics AB 2022